Pharmaceutical Executive

🚨Our March issue is LIVE🚨 Learn about immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics in our cover profile🔷 Sourcing, nurturing, and retaining talent🔷Making HCP analytics actually work for commercial teams🔷and much more right here➡️pharmexec.com/journals/pharm…

A new all-oral treatment option for AML has entered the FDA-approved landscape. The FDA approved Inqovi in combination with venetoclax as the first and only all-oral combination treatment regimen for certain patients with acute myeloid leukemia. #Pharma #AML #FDA

Explore how ACTO is elevating sales effectiveness across life sciences—empowering over 50,000 field professionals to deliver confident, compliant HCP interactions. From global pharma leaders to emerging biotech, discover strategies driving field excellence: hubs.li/Q04c1q4G0 #LifeSciences

AI search is reshaping how healthcare brands get discovered. Join Victoria Houston and Mark Traphagen to learn: • How AI Overviews shape patient + HCP discovery • Why brand content gets misrepresented in AI answers • The SEO signals that influence what AI surfaces • How to track and improve AI visibility at scale Register here:hubs.li/Q04fSk_W0

Sustainability, safety, and precision are redefining pharma logistics—innovations in cold chain and last-mile delivery are ensuring therapies reach patients reliably and responsibly. #PharmaLogistics hubs.li/Q04dYk7p0

🚨 PE Spotlight: Bringing Hepatitis B innovation to scale in China GSK teams up with SBP Group’s CTTQ unit to support Bepirovirsen’s launch across 5,000+ medical centers in mainland China. 🔗 Read more: hubs.li/Q04gcMPd0 #PharmExec #PESpotlight #HepatitisB #Biotech #DrugDevelopment

“The patient is at the heart of everything we do.” Jessica Lovett, VP of commercial strategy and innovation at Innomar, discusses the core principle she keeps in mind when developing strategies. Watch the video below and explore more shorts here:hubs.li/Q04fZsrQ0 #PharmExec #PatientCare #HealthcareInnovation #PharmaIndustry #CommercialStrategy

Why does the US healthcare system feel so disconnected? Will Shrank breaks down how fragmentation across payers, providers, and patients is driving inefficiencies and rising costs. Watch the below to hear more. #PharmExec #Healthcare #TrendingPharma

We recently welcomed Jesse Mendelsohn (SVP, Model N) to MJH Studios 🎙️ He joined Mike Christel to break down the complex relationship between PBMs and manufacturers in our Pricing & Policy series. Check out our debut episode: hubs.li/Q04fkGxw0 Episode 2 coming soon 👀 #PharmExec #Pharma #HealthcarePolicy #PBM

In this short, Jeff Golfman, founder and president of Send 123, explains why moving away from just-in-time models can strengthen supply chain resilience, reduce risk exposure, and improve operational stability. 📺 Watch the clip below! #PharmExec #SupplyChain #Logistics

Legacy patient support models are driving delays and drop-offs—automation and integrated workflows can reduce friction, speed time to therapy, and improve conversion. #PatientAccess hubs.li/Q04c8Mrl0

🚨 PE Spotlight: How does the Strait of Hormuz factor into pharmaceutical risk? Geralyn Ritter and Monica Gorman examine how this critical passage connects to pharmaceutical supply chains and the movement of key materials. 🔗 See how the Strait of Hormuz is influencing pharma: hubs.li/Q04f1mhz0 #TrendingPharma #SupplyChain #RiskManagement #Geopolitics

Innovation is driven by people & great work deserves recognition. 🚨 Last call: Nominate a rising leader for the Emerging Pharma Leaders Awards (sponsored by BGB Group) before May 1st: hubs.li/Q04dKNFQ0 Thank you to all who’ve submitted! We’re excited to select our winners! #PharmExec #EmergingPharmaLeaders #Innovation #Leadership

Don’t miss this chance to learn how biopharma teams are speeding up early-stage research and reducing risk. Save your spot and register today: hubs.li/Q04cKxmV0

🚨 PE Spotlight: Drug pricing is under renewed political pressure ahead of the U.S. midterms. At Asembia AXS26, experts discussed FTC scrutiny of PBMs, rebate reform, and shifting compensation models that could reshape the U.S. drug pricing system. 🔗 Find out more: hubs.li/Q04dNXlK0 #PharmExec #PESpotlight #AXS26 #DrugPricing

What does the future of patient-centric manufacturing look like in CGT? Maher Masoud, CEO of MaxCyte, explains how platform technologies and partnerships are shaping development. Watch this short and more ➡️ hubs.li/Q04dCFN20 #Pharma #CGT #Biotech

Copay misuse is costing pharma billions—but real-time prevention is changing the game. Ensure funds reach the right patients while protecting your spend. #PatientAccess hubs.li/Q049Vb050

Is talent acquisition the missing edge in brand strategy? In a Pharm Exec discussion, Andy Milligan of The Caffeine Partnership points to an untapped opportunity life sciences brands may be overlooking. Listen to the full discussion: hubs.li/Q04dq4dN0 #PESpotlight #TrendingPharma #TalentAcquisition

Struggling to move from hypothesis to insight fast enough? See how teams are turning research questions into structured, reproducible analysis in minutes. Register now: hubs.li/Q04cKCnv0

🚨 PE Spotlight: Middle East tensions expose fragile pharma supply chains. USP data shows nearly half of critical U.S. medicines rely on a single-country source for key ingredients. Can the industry respond before shortages hit hospitals? Find out more 🔗 : hubs.li/Q04d2ByB0 #PharmExec #PESpotlight #SupplyChain #DrugShortages

Explore how ACTO is elevating sales effectiveness across life sciences—empowering over 50,000 field professionals to deliver confident, compliant HCP interactions. From global pharma leaders to emerging biotech, discover strategies driving field excellence: hubs.li/Q04d0MKV0 #LifeSciences